Cargando…
Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments
OBJECTIVES: To evaluate the efficacy and safety of ustekinumab (UST) in a multicentre, randomised, double-blind, placebo-controlled trial in adult Japanese patients with active polymyositis (PM) and dermatomyositis (DM). METHODS: Fifty-one Japanese adults diagnosed with active PM/DM who did not resp...
Autores principales: | Kawahata, Kimito, Ishii, Tomonori, Gono, Takahisa, Tsuchiya, Yumi, Ohashi, Hiroki, Yoshizawa, Katsunori, Zheng, Richuan, Ayabe, Maori, Nishikawa, Kazuko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476119/ https://www.ncbi.nlm.nih.gov/pubmed/37652554 http://dx.doi.org/10.1136/rmdopen-2023-003268 |
Ejemplares similares
-
[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019) -
Immunoproteasome subunit β5i promotes perifascicular muscle atrophy in dermatomyositis by upregulating RIG-I
por: Zhang, Lu, et al.
Publicado: (2023) -
Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023) -
Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis
por: Oto, Yohsuke, et al.
Publicado: (2023) -
Aberrant Muscle Antigen Exposure in Mice Is Sufficient to Cause Myositis in a Treg Cell–Deficient Milieu
por: Young, Nicholas A, et al.
Publicado: (2013)